Claims for Patent: 7,910,605

Summary for Patent: 7,910,605

Title:	Non-imidazole alkylamines as histamine H.sub.3- receptor ligands and their therapeutic applications
Abstract:	Use of a compound of formula (A), wherein: ##STR00001## W is a residue which imparts antagonistic and/or agonistic activity at histamine H.sub.3-receptors when attached to an imidazole ring in 4(5) position; R.sup.1 and R.sup.2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H.sub.3-receptors of histamine.
Inventor(s):	Schwartz; Jean-Charles (Paris, FR), Arrang; Jean-Michel (Dourdon, FR), Garbarg; Monique (Paris, FR), Lecomte; Jeanne-Marie (Paris, FR), Ligneau; Xavier (Paris, FR), Schunack; Walter G. (Berlin, DE), Stark; Holger (Berlin, DE), Ganellin; Charon Robin (Welwyn, GB), Leurquin; Fabien (London, GB), Elz; Sigurd (Berlin, DE)
Assignee:	Societe Civile Bioprojet (Paris, FR)
Application Number:	11/478,682
Patent Claims:	1. A method for treating symptoms associated with cognitive disorders selected from the group consisting of attention, wakefulness and memory disorders, said method comprising administering, in an amount effective to inhibit H3 receptor activity, a compound of formula (IIa) as defined below: ##STR00312## wherein: R.sup.1 and R.sup.2 form together with the nitrogen to which they are attached a saturated nitrogen-containing ring ##STR00313## with m ranging from 4 to 5 and R.sup.a-b being independently a hydrogen atom or a lower alkyl, and (i') the chain A.sup.II selected from an unbranched alkyl group --(CH.sub.2).sub.nII-- where n.sub.II is 3 (ii') the group X'' is --O--; (iii') the chain B.sup.II is an unbranched alkyl comprising 3 carbon atoms; and (iv') the group Y.sup.II represents a phenyl group, unsubstituted or mono- or polysubstituted with one or more identical or different substituents selected from halogen atoms, OCF.sub.3, CHO, CF.sub.3, SO.sub.2N(alkyl).sub.2, NO.sub.2, S(aryl), SCH.sub.2(phenyl), an unbranched or branched alkene, an unbranched or branched alkyne optionally substituted with a trialkylsilyl radical, --O(alkyl), --O(aryl), --CH.sub.2CN, a ketone, an aldehyde, a sulphone, an acetal, an alcohol, a lower alkyl, --CH.dbd.CH--CHO, --C(alkyl).dbd.N--OH, --C(alkyl).dbd.N--O(alkyl) and, --CH.dbd.NOH, --CH.dbd.NO(alkyl), --C(alkyl)=NH--NH--CONH.sub.2, an O-phenyl or --OCH.sub.2(phenyl) group, --C(cycloalkyl)=NOH, --C(cycloalkyl)=N--O(alkyl); or its pharmaceutically acceptable salts, or their optical isomers, racemates, diastereoisomers or enantiomers; to a patient in need thereof. 2. The method according to claim 1 using 3-(4-chlorphenyl)propyl-3-piperidinopropylether, or its pharmaceutically acceptable salts, or its optical isomers, racemates, diastereoisomers or enantiomers. 3. The method according to claim 1, wherein the symptoms associated with cognitive disorders are attention, wakefulness and/or memorization disorders associated with Alzheimer disease. 4. The method according to claim 3 where the symptoms occur in aged persons. 5. The method according to claim 1 wherein the compound is in the form of a pharmaceutical salt selected from the group consisting of hydrochloride, hydrobromide, hydrogen maleate and hydrogen oxalate. 6. The method according to claim 2 wherein the compound is in the form of a pharmaceutical salt selected from the group consisting of hydrochloride, hydrobromide, hydrogen maleate and hydrogen oxalate.